It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

Othman T, Frankel P, Allen P, et al. Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica . 2025;110(1):142 ...

Pegvorhyaluronidase alfa, a pegylated version of Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20 ... alfa with Tecentriq (atezolizumab), which is normally used for the treatment ...

Exelixis (EXEL) announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination with atezolizumab in patients with previously ...

NICE is unable to make a recommendation about the use in the NHS of atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in ...

having secured European approvals for its subcutaneous vial and syringe formulation of Tecentriq (atezolizumab) – also based on Halozyme’s hyaluronidase technology – for all indications of ...

Patients received oral cabozantinib 40 mg once daily and intravenous atezolizumab 1,200 mg once every 3 weeks. The primary end point was objective response rate (ORR), as assessed by the investigator ...